

Karolina Woroniecka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10950705/publications.pdf>

Version: 2024-02-01

13
papers

1,027
citations

1307594

7
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

1924
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. <i>Nature Medicine</i> , 2018, 24, 1459-1468.	30.7	437
2	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 4175-4186.	7.0	402
3	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 774-788.	8.2	47
4	Prospect of rindopepimut in the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 507-513.	3.1	40
5	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 579-591.	3.1	37
6	T-cell exhaustion in glioblastoma. <i>Oncotarget</i> , 2018, 9, 35287-35288.	1.8	30
7	Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1233-1234.	1.2	13
8	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	3.1	8
9	Palliative Care. <i>Academic Medicine</i> , 2015, 90, 364.	1.6	1
10	BSCI-07. BONE MARROW T-CELL SEQUESTRATION IN THE SETTING OF BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i2-i2.	0.7	1
11	4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma. <i>Oncoscience</i> , 2020, 7, 34-35.	2.2	1
12	IMST-08. EXPRESSION OF PDL-1 ON PITUITARY ADENOMAS: AÂROLE FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2016, 18, vi87-vi87.	1.2	0
13	BSCI-03. T CELL EXHAUSTION SIGNATURES VARY BY TUMOR TYPE AND ARE INDEPENDENT OF INTRACRANIAL LOCATION. <i>Neuro-Oncology Advances</i> , 2019, 1, i1-i1.	0.7	0